UK markets close in 7 hours 43 minutes
  • FTSE 100

    7,101.88
    +20.16 (+0.28%)
     
  • FTSE 250

    23,240.52
    +31.85 (+0.14%)
     
  • AIM

    1,258.63
    +1.02 (+0.08%)
     
  • GBP/EUR

    1.1709
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.3914
    +0.0031 (+0.22%)
     
  • BTC-GBP

    27,722.67
    -1,197.72 (-4.14%)
     
  • CMC Crypto 200

    936.78
    -24.12 (-2.51%)
     
  • S&P 500

    4,387.16
    -8.10 (-0.18%)
     
  • DOW

    34,838.16
    -97.31 (-0.28%)
     
  • CRUDE OIL

    71.32
    +0.06 (+0.08%)
     
  • GOLD FUTURES

    1,812.20
    -10.00 (-0.55%)
     
  • NIKKEI 225

    27,641.83
    -139.19 (-0.50%)
     
  • HANG SENG

    26,137.56
    -98.24 (-0.37%)
     
  • DAX

    15,561.49
    -7.24 (-0.05%)
     
  • CAC 40

    6,722.57
    +46.67 (+0.70%)
     

Global NK Cell Therapies Pipeline Market Report 2021 - ResearchAndMarkets.com

·6-min read

DUBLIN, Jun 14, 2021--(BUSINESS WIRE)--The "NK Cell Therapies - Pipeline Insight, 2021" drug pipelines report has been added to ResearchAndMarkets.com's offering.

This "NK Cell therapy - Pipeline Insight, 2021," report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve NK Cell therapy.

NK Cell therapy Emerging Drugs Chapters

This segment of the NK Cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NK Cell therapy Emerging Drugs

Monalizumab: Innate Pharma

Monalizumab (also known as IPH2201) is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic NK and CD8 T lymphocytes. It is under development by Innate Pharma in Phase III stage for the treatment of Squamous Cell Carcinoma of the Head and Neck and in Phase II stage of development for the treatment of gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. It is in the Phase I stage of development for the treatment of advanced solid tumors and hematological malignancies.

NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

Nectar Therapeutics is developing NKTR-214 which is an intravenously administered, investigational, engineered IL-2 cytokine for the treatment of solid tumors. NKTR-214 is designed to grow specific cancer-killing T-cells and natural killer cell populations in the body that fight cancer is known as endogenous tumor-infiltering lymphocytes (TILs). NKTR-214 stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of these effector T cells.

ALECSAT: CytoVac

ALECSAT (Autologous Lymphoid Effector Cells Specific against Tumor-cells) is a therapy that supplements and strengthens the patient's immune system so it can fight the cancer cells in the same way as the body originally should have reacted. Natural Killer Cells used, in the ALECSAT therapy attack, the cancer cells in several ways, as they can recognize more than one property of the cancer cells. ALECAST is being evaluated for breast cancer and newly diagnosed glioblastoma in Phase II.

CellProtect: XNK Therapeutics

CellProtect is a novel cell therapy based on autologous NK cells that are expanded and their cytotoxic activity restored through a patented process. The cells are then infused into the patient to treat the disease. Cell Protect is under development by CellProtect Nordic Pharmaceuticals and is currently in Phase II stage for the treatment of Multiple Myeloma at the Karolinska University Hospital in Huddinge, Sweden and Sanofi's support by providing Sarclisa. It is manufactured under GMP conditions at the core facility Vecura at Karolinska University Hospital.

NK-92: ImmunityBio

NK-92 also known as aNK is activated natural killer (NK) cells and administered intravenously. It is the only cell line that can be commercialized as a direct, scalable and off-the-shelf product, which attacks and kills abnormal cells on contact. NK-92 does not require an intact immune system for killing the diseased cells in the body. It targets NK ligand and activates its action. NK-92 cells are also being engineered to target specific cancers and also to express a receptor that will couple with monoclonal antibodies to enhance their cancer-killing effects. NK-92 is being evaluated in Phase II stage of development for the treatment of stage IIIB & IV Merkel cell carcinoma as monotherapy and in combination with ALT-803, in Phase I stage of development for acute myeloid leukemia, Hematological Malignancies and solid tumors and in the Pre-IND phase for hepatocellular carcinoma and infectious disease.

haNk: ImmunityBio

haNK (also known as high-affinity Natural killer cells) is a genetically engineered and modified aNK cells that incorporates high-affinity CD16 receptors (V158 FcγRIIIa) and bind to antibodies. The therapeutic candidate targets CD16 and results in the killing of cancerous cells by process of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). haNK is further engineered to express IL-2. These cells enhanced Perforin and granzyme-medied killing of tumor cells, as well as support the expansion of NK cell populations. haNK is under development by NantKwest and is in the Phase II stage of development for the treatment of cancer. The company is developing the drug by using Antibody-mediated Killing: haNK Platform.

K-NK002: Kiadis Pharma

K-NK002 is a natural killer cell-based immuno-oncology therapy. The molecule is made up of company's proprietary off-the-shelf NK-cell platform. K-NK002 is an NK cell product derived from peripheral blood leukocytes collected from a related donor (HLA-haploidentical matched) and enriched for NK cells with depletion of CD3+ T-lymphocytes (T-cells) followed by enriched ex-vivo expansion. K-NK002 is under Phase II clinical development by Kiadis Pharma for the treatment of acute myeloid leukemia and Myelodysplastic syndromes. CytoSen's lead NK-cell therapy candidate, CSDT002-NK is now known as K-NK002 after the company being acquired by Kiadis Pharma in 2019.

Companies Mentioned

  • Abivax

  • Acepodia

  • Affimed Therapeutics AG

  • Agenus

  • Allife Medical Science and Technology

  • Artiva Biotherapeutics

  • Asclepius Technology Company Group

  • Bellicum Pharmaceuticals

  • Bright Path Biotherapeutics

  • Bristol-Myers Squibb

  • Cantargia

  • CARsgen therapeutics

  • Celgene Corporation/Celularity

  • Cellid Company

  • Celularity

  • Celyad Oncology

  • Chongqing Sidemu Biotechnology

  • CiMass

  • CureTech

  • CytoImmune Therapeutics

  • CytoVac

  • Cytovia Therapeutics

  • Dragonfly Therapeutics

  • Dynavax

  • Exacis Biotherapeutics

  • Fate Therapeutics

  • Feldan Therapeutics

  • Five Prime Therapeutics

  • Glycostem

  • Glycostem Therapeutics (IPD Therapeutic)

  • Green Cross Corporation

  • GT Biopharma

  • HiberCell

  • iCell Gene Therapeutics

  • ImmunityBio

  • Innate Pharma

  • Kiadis Pharma

  • Kuur Therapeutics (Formerly Cell Medica)

  • Multimmune GmbH

  • NantKwest

  • Nektar Therapeutics

  • NKMax

  • ONK Therapeutics

  • Orgenesis

  • PersonGen BioTherapeutics (Suzhou)

  • Surface Oncology

  • Synimmune

  • Vycellix

  • XNK Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/po3w4l

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005602/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting